{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:45:56Z","timestamp":1792856756785,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.arbres.2025.10.004","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T06:36:29Z","timestamp":1760078189000},"page":"301-309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Nintedanib Combined With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis: A Long-Term Retrospective Multicentre Study (Combi-PF)"],"prefix":"10.1016","volume":"62","author":[{"given":"Corentin","family":"Meersseman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Mart\u00ednez Besteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Romain-Scelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Crestani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Marchand-Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilario","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidwine","family":"W\u00e9meau-Stervinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Borie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Diesler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2025.10.004_bib0200","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2025.10.004_bib0205","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0100-2018","article-title":"Fibrosing interstitial lung diseases: knowns and unknowns","volume":"28","author":"Cottin","year":"2019","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.arbres.2025.10.004_bib0210","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of fibrotic lung diseases","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2025.10.004_bib0215","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00692-2018","article-title":"What's in a name? That which we call IPF, by any other name would act the same","volume":"51","author":"Wells","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2025.10.004_bib0220","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03187-2021","article-title":"Progressive pulmonary fibrosis: an expert group consensus statement","volume":"61","author":"Rajan","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2025.10.004_bib0225","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/MCP.0000000000000908","article-title":"Epidemiology and real-life experience in progressive pulmonary fibrosis","volume":"28","author":"Valenzuela","year":"2022","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.arbres.2025.10.004_bib0230","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2025.10.004_bib0235","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2025.10.004_bib0240","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.chest.2021.06.049","article-title":"Impact of antifibrotic therapy on mortality and acute exacerbation in idiopathic pulmonary fibrosis","volume":"160","author":"Petnak","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2025.10.004_bib0245","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2025.10.004_bib0250","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2025.10.004_bib0255","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2025.10.004_bib0260","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejps.2014.02.014","article-title":"Effect of pirfenidone on proliferation. TGF-\u03b2-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts","volume":"58","author":"Conte","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.arbres.2025.10.004_bib0265","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.113.208223","article-title":"Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis","volume":"349","author":"Wollin","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.arbres.2025.10.004_bib0270","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1096\/fj.201600892RR","article-title":"Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors","volume":"31","author":"Didiasova","year":"2017","journal-title":"FASEB J"},{"key":"10.1016\/j.arbres.2025.10.004_bib0275","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12931-016-0328-5","article-title":"Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis","volume":"17","author":"Lehtonen","year":"2016","journal-title":"Respir Res"},{"key":"10.1016\/j.arbres.2025.10.004_bib0280","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1165\/rcmb.2016-0217OC","article-title":"A novel antifibrotic mechanism of nintedanib and pirfenidone. Inhibition of collagen fibril assembly","volume":"57","author":"Kn\u00fcppel","year":"2017","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.arbres.2025.10.004_bib0285","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1183\/09031936.00198013","article-title":"Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis","volume":"45","author":"Ogura","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2025.10.004_bib0290","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01060-2018","article-title":"No relevant pharmacokinetic drug\u2013drug interaction between nintedanib and pirfenidone","volume":"53","author":"Richeldi","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2025.10.004_bib0295","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s12325-021-01961-x","article-title":"Treatment of idiopathic pulmonary fibrosis with capsule or tablet formulations of pirfenidone in the real-life French RaDiCo-ILD cohort","volume":"39","author":"Cottin","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.arbres.2025.10.004_bib0300","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000496735","article-title":"A 2-year observational study in patients suffering from idiopathic pulmonary fibrosis and treated with pirfenidone: a French ancillary study of PASSPORT","volume":"98","author":"Jouneau","year":"2019","journal-title":"Respiration"},{"key":"10.1016\/j.arbres.2025.10.004_bib0305","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1007\/s12325-023-02454-9","article-title":"A narrative review of real-world data on the safety of nintedanib in patients with idiopathic pulmonary fibrosis","volume":"40","author":"Podolanczuk","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.arbres.2025.10.004_bib0310","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1164\/rccm.201706-1301OC","article-title":"Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis. Results of the INJOURNEY trial","volume":"197","author":"Vancheri","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2025.10.004_bib0315","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.resinv.2021.04.005","article-title":"Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: a multicenter retrospective observational study in Japan","volume":"59","author":"Hisata","year":"2021","journal-title":"Respir Investig"},{"key":"10.1016\/j.arbres.2025.10.004_bib0320","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00230-2018","article-title":"Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis","volume":"52","author":"Flaherty","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2025.10.004_bib0325","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1183\/13993003.00026-2015","article-title":"Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials","volume":"47","author":"Noble","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2025.10.004_bib0330","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/jcm5090078","article-title":"Real world experiences: pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis","volume":"5","author":"Hughes","year":"2016","journal-title":"J Clin Med"},{"key":"10.1016\/j.arbres.2025.10.004_bib0335","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12144635","article-title":"A real-world multicenter retrospective observational study on polish experience with nintedanib therapy in patients with idiopathic pulmonary fibrosis: the PolExNIB study","volume":"12","author":"Majewski","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.arbres.2025.10.004_bib0340","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000485933","article-title":"Real-world experience with nintedanib in patients with idiopathic pulmonary fibrosis","volume":"95","author":"Brunnemer","year":"2018","journal-title":"Respiration"},{"key":"10.1016\/j.arbres.2025.10.004_bib0345","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000029232","article-title":"Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration","volume":"101","author":"Ikeda","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.arbres.2025.10.004_bib0350","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.21037\/jtd-23-946","article-title":"Safety and tolerability of combination treatment with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis","volume":"15","author":"Lee","year":"2023","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.arbres.2025.10.004_bib0355","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1301923","article-title":"Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis","volume":"14","author":"Huh","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.arbres.2025.10.004_bib0360","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s12931-020-01528-4","article-title":"Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis","volume":"21","author":"Jouneau","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.arbres.2025.10.004_bib0365","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1007\/s10238-023-01212-z","article-title":"Clinical effect of progressive pulmonary fibrosis on patients with connective tissue disease-associated interstitial lung disease: a single center retrospective cohort study","volume":"23","author":"Lee","year":"2023","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.arbres.2025.10.004_bib0370","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/bdd.311","article-title":"Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration","volume":"23","author":"Giri","year":"2002","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.arbres.2025.10.004_bib0375","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s40262-019-00766-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of nintedanib","volume":"58","author":"Wind","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.arbres.2025.10.004_bib0380","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2023-001687","article-title":"Antifibrotic treatment adherence, efficacy and outcomes for patients with idiopathic pulmonary fibrosis in Spain: a real-world evidence study","volume":"11","author":"Romero Ortiz","year":"2024","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.arbres.2025.10.004_bib0385","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00503-2018","article-title":"Effect of antifibrotics on short-term outcome after bilateral lung transplantation: a multicentre analysis","volume":"51","author":"Lambers","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2025.10.004_bib0390","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.healun.2017.07.002","article-title":"Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy","volume":"37","author":"Leuschner","year":"2018","journal-title":"J Heart Lung Transplant"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289625003552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289625003552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T20:48:45Z","timestamp":1777754925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289625003552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0300289625003552"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2025.10.004","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nintedanib Combined With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis: A Long-Term Retrospective Multicentre Study (Combi-PF)","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2025.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Espa\u00f1a, S.L.U. on behalf of SEPAR.","name":"copyright","label":"Copyright"}]}}